RECOVERY & TISSUE REPAIR / FAQ
Questions From the Literature
Direct, citation-anchored answers to the questions readers most often bring to these four recovery compounds.
What does BPC-157 do in the body?
In animal models, BPC-157 is described as a cytoprotective and regenerative peptide. Its repair effects are tied most consistently to angiogenesis — encouraging new blood-vessel growth into injured tissue by increasing VEGFR2 receptor expression and activating the downstream VEGFR2-Akt-eNOS pathway [4]. It has accelerated healing in rat models of gastric ulcers [5] and transected Achilles tendon [6], and it modulates brain-gut signaling and serotonergic and dopaminergic systems [7]. Crucially, almost all of this is preclinical; human evidence is limited to three small pilot studies as of the most recent reviews [2].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and is not growth hormone in any form. It is a synthetic fifteen-amino-acid peptide derived from a gastric-juice protein. There is one overlap that sometimes causes confusion: in tendon fibroblasts, BPC-157 has been reported to sensitize the growth-hormone receptor, potentially amplifying the body's own growth-hormone signaling [7]. Sensitizing a receptor is not the same as being a hormone; BPC-157 does not replace or act as growth hormone itself.
Does BPC-157 work immediately?
The compound clears from the bloodstream quickly — pharmacokinetic work in rats and dogs found an elimination half-life under 30 minutes, with rapid breakdown into small fragments that re-enter amino-acid metabolism [3]. A short half-life means the intact peptide does not linger after dosing. Whether any healing effect manifests quickly is a separate question; published animal healing data are measured over days to weeks, not immediate human outcomes [6]. This desk does not advise on use or timing.
Does BPC-157 damage the liver?
The available data do not show liver harm — but those data are very thin. In the 2025 first-in-human intravenous safety pilot, BPC-157 up to 20 mg in two healthy adults produced no measurable changes in hepatic biomarkers, no cardiac, renal, thyroid or glucose changes, and no adverse events [1]. That is reassuring, but it is two people in a safety pilot, not a liver-safety study. The broader literature stresses that without long-term, large-sample human data the overall safety profile remains genuinely unknown [2]. Nothing on this page is medical advice.
What is TB-500?
TB-500 is a synthetic seven-amino-acid peptide, Ac-LKKTETQ, corresponding to the actin-binding region (residues 17-23) of thymosin beta-4. "TB" refers to thymosin beta — specifically thymosin beta-4 (Tβ4), the full-length natural protein. TB-500 is the short fragment; the full protein is roughly five times larger [8][12]. In commerce and in anti-doping assays, "TB-500" means the heptapeptide. In most published efficacy research, the compound tested was the intact Tβ4 protein. So the name points at a fragment while much of its cited reputation rests on the whole protein.
What does TB-500 stand for and what does TB stand for in TB-500?
"TB" is short for thymosin beta. TB-500 is a research designation for the synthetic Ac-LKKTETQ heptapeptide fragment of thymosin beta-4 (also called Tβ4). The fragment was historically associated with veterinary-context preparations; "TB1000" is a related veterinary designation. The "500" has no standardized meaning in the primary literature — it is a commercial label, not an IUPAC designation. The important distinction is that TB-500 (the 7-mer fragment) and thymosin beta-4 (the full 43-amino-acid protein) are different molecules with different molecular weights [12].
What is TB-500 used for in research?
In research, TB-500 (and more often full-length thymosin beta-4) is studied for tissue repair mediated by actin regulation: cell migration, new blood-vessel growth, reduced scar formation, and anti-inflammatory signaling across dermal-wound, corneal, cardiac and CNS models [10]. A human Phase 1 study of full-length Tβ4 in 40 volunteers established safety and pharmacokinetics rather than disease efficacy [11], and a rat stroke study examined neurological recovery dose-response [9]. There are no completed controlled clinical trials of the TB-500 fragment itself for any indication [8].
Does TB-500 work for muscle tears and recovery from exercise?
There is no controlled human evidence that the TB-500 fragment helps with muscle tears or exercise recovery. The mechanistic rationale comes from thymosin beta-4's role in actin-driven cell migration and repair [10], but a 2026 Sports Medicine review of unapproved peptides for musculoskeletal injury and athletic performance concluded that favorable animal results have not been matched by rigorous human safety or efficacy data, with potential for serious harm and no regulatory oversight [8]. Notably, in a muscular-dystrophy mouse model chronic Tβ4 increased regenerating fibers but did not improve muscle strength [10]. TB-500 is also banned in sport [8].
What does a GHK-Cu peptide do?
GHK-Cu does two things at once: it delivers copper to tissue and it signals repair. At picomolar-to-nanomolar concentrations it stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans and decorin, while rebalancing the enzymes that degrade the matrix against their inhibitors; the copper enables collagen/elastin cross-linking and an antioxidant function [16]. At the gene level it shifts expression of roughly 31.2% of human genes (at a 50%-or-greater change threshold) toward repair, DNA-repair and antioxidant programs [14]. Most of its documented human benefit is in topical skin applications [13].
What is GHK-Cu and how does it work?
GHK-Cu is the linear tripeptide glycyl-L-histidyl-L-lysine chelated 1:1 to a copper(II) ion. That copper is coordinated through the histidine imidazole, the glycine amino group and a backbone nitrogen, leaving the lysine side chain free. At the cellular level it works by acting both as a copper chaperone — delivering Cu(II) for lysyl-oxidase-catalyzed collagen and elastin cross-linking — and as a direct transcriptional signal to dermal fibroblasts to upregulate matrix synthesis [16]. Its gene-expression effects span ubiquitin-proteasome, DNA-repair, and antioxidant programs; the copper coordination is required for most reported bioactivities, so GHK and GHK-Cu are not interchangeable [14].
Is GHK-Cu peptide really anti-aging?
There is real, if modest and mostly topical, human evidence for skin benefits. Topical GHK-Cu increased collagen production in about 70% of treated women, outperforming vitamin C (50%) and retinoic acid (40%) in the same comparison, with documented placebo-controlled improvements in skin laxity, clarity, fine lines and wrinkle depth [16]. Two honest caveats: the dramatic "~4,000 genes" claim is an extrapolation from a verified figure of roughly 2,100 genes at the measured 50%-change threshold [14], and the peptide penetrates intact skin poorly, limiting dermal delivery without aids like microneedling or palmitoylation [13]. Systemic "anti-aging" use is unproven.
What is the difference between GHK and GHK-Cu?
GHK is the bare tripeptide glycyl-histidyl-lysine; GHK-Cu is that same tripeptide chelated to a copper(II) ion in a 1:1 coordinate complex. The difference is not cosmetic — copper coordination is required for most of GHK's reported bioactivities, including collagen stimulation, cross-linking and antioxidant effects, so the form used in a given study genuinely matters [16]. The two are frequently conflated in secondary sources, but in the primary literature the copper complex (GHK-Cu) is the active form for the matrix-repair and gene-expression claims.
What is KLOW peptide?
KLOW is a co-formulated, lyophilized research blend combining four peptides in a single vial: KPV (anti-inflammatory tripeptide from alpha-MSH), GHK-Cu (copper tripeptide-1), BPC-157 (stable gastric pentadecapeptide), and TB-500 (thymosin beta-4 actin-binding fragment). The four are chemically distinct molecules that do not form a single compound. The most widely cited research-vial composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. It is a research-only co-formulation; no FDA-approved KLOW combination product exists [8][18].
What is KLOW peptide used for?
KLOW's combination rationale is mechanistic: the four arms are proposed to cover complementary repair stages — NF-kB/MAPK inflammation suppression (KPV), matrix synthesis and copper delivery (GHK-Cu), angiogenesis via VEGFR2 (BPC-157), and actin-driven cell migration (TB-500/Tβ4). In research-use communities it is most associated with connective-tissue recovery — tendons, joints, gut mucosa — though all such accounts are anecdotal. Critically, the blend itself has never been tested in any controlled study, so claims of synergy or superiority over individual components are extrapolation, not experimental findings [8][1].
Where do you inject KLOW peptide?
This desk does not advise on route, site, dose or schedule for any compound. KLOW and all four of its components are sold for laboratory research use only and are not approved medicines. No human injection protocol has been validated in any controlled clinical trial. Route-of-administration information for the individual components appears only as recorded in the specific studies — e.g., BPC-157 studied IM or IV in animals or a 2-person human pilot [3][1], thymosin beta-4 studied IV in a human Phase 1 trial [11]. Reporting how a compound was studied is not a recommendation for how it should be used.
How much KLOW peptide per day?
This desk does not provide human dosing recommendations for any compound, and none exists in the controlled clinical literature for the KLOW blend. Each component has an individual pharmacokinetic profile: BPC-157 has an elimination half-life under 30 minutes [3], the tripeptides KPV and GHK-Cu clear even faster, and the TB-500 fragment behaves differently from native thymosin beta-4. A single co-formulated vial cannot hold all four at matched effective exposures over time. Any dosing protocol circulating in communities is anecdotal and has no experimental support. This page is a research digest; it is not medical guidance.